SequelSEC

Regen BioPharma Inc RGBP

Pharmaceutical Preparations · CIK 0001589150 · Fiscal year ends 0930

AnnualQuarterlyTTM
Revenue
$236.56K
Fiscal year ended 2026-06-30
Operating income
-$803.86K
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$1.05MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-03-31
Float per share$0.01Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue4.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-03-31, not today, and each multiple below it uses the figures for the fiscal year ending 2025-09-30 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio0.04x3th
R&D / revenue5.0%6th
Operating margin-143.1%55th
Revenue YoY growth0.0%46th

Regen BioPharma Inc (RGBP) reported revenue of $236.56K and net income of -$1.19M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Regen BioPharma Inc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Regen BioPharma Inc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$236.56K
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$803.86K
Net income-$1.19M
Research & development$223.94K
Weighted-average diluted sharesUnavailable
Pretax income-$1.19M
Income tax expense$0
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$295.62K
Selling & marketingUnavailable

Balance

Regen BioPharma Inc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$239
Total assets$287.59K
Current assets$287.59K
Total liabilities$6.17M
Current liabilities$6.17M
Total equity incl. NCI-$5.88M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$287.15K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$20.62K

Cash flow

Regen BioPharma Inc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$445.25K
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$443.73K
Net change in cash-$1.52K
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Regen BioPharma Inc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-339.8%
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.05x
Revenue YoY growth0.0%
Net margin-501.4%
R&D / revenue94.7%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RGBP in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-17View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-Q · Filed 2026-02-13View SEC filing
10-K · Filed 2025-12-30View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-28View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.